Modus Therapeutics publishes interim report for the first quarter 2022
STOCKHOLM, SWEDEN - 16 May 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2022. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.The first quarter in figures · The loss after tax amounted to TSEK 3 065 (1 428). · The loss per share amounted to SEK 0,19 (0,17). · The cash flow from current operations was negative in the amount of TSEK 7 545 (1 166). Important events during the quarter · Modus presented at Erik Penser